OptiNose to Present at Innovations in Healthcare Executive Forum
YARDLEY, PA, March 30, 2015— OptiNose today announced that the company will present at the Innovations in Healthcare Executive Forum on Tuesday, April 28, 2015. President and COO, Ramy Mahmoud has been invited to participate in the conference, which brings influencers from the provider, payer, pharmaceutical, med-tech, bio-tech and the investment communities together from all over the world.
"Healthcare today is at a crossroads, with old ideas, incentives, systems and structures all being questioned," said Ramy Mahmoud, MD, MPH. "While some in the industry are of the mind that significant innovation is too costly, our view is that sticking with the status quo or failing to innovate may cost even more. I look forward to sharing the innovation story of OptiNose, and how we are working to improve health and healthcare by starting with a simple but elegant new form of drug delivery and using unusual ideas about how to do business to produce remarkable results."
Dr. Mahmoud will participate in a Panel Discussion: Implementing Disruptive Innovation Strategies to Improve Patient Care. In this interactive session we will hear real stories and case-studies as to how organizations are using disruptive innovation to improve quality, lower costs, extend patients' lives and lead to cures.
To learn more about the conference, please visit: http://msepartners.com/healthcare/index.php?id=april-28
Dr. Mahmoud will present at 2:30 p.m. at the Peabody Hotel in Memphis, Tennessee.
OptiNose is a Specialty Pharmaceutical Company developing a promising pipeline of late stage new products. The Company's patented Bi-Directional™ Breath Powered™ technology platform creates differentiated treatments by enabling deep intranasal drug deposition. OptiNose successfully out-licensed a first product at the end of phase 3 (AVP-825 for Migraine, licensed to AVNR in North America), and has proven clinical success with other products, including OPN-375, a treatment for Chronic Nasal Inflammatory Diseases (CNID) that will soon complete Phase 3. OPN-375 has the potential to be a breakthrough that creates a new standard of care for the treatment of serious CNID, such as Chronic Sinusitis. Other OptiNose pipeline products also target large and attractive markets with significant unmet need, including nose-to-brain technology applications such as OPN-300 for Autism. OptiNose has corporate offices in the US, Norway and the UK.
About OptiNose's Bi-Directional™ Breath Powered™ Delivery Technology
OptiNose's patented closed-palate Bi-Directional Breath Powered delivery technology is unique in that it uses the natural function of a user's breath to propel medications beyond the nasal valve into the deep, targeted areas of the nasal cavity more effectively and efficiently than current treatment approaches. A user exhales into the device, creating a natural closure of the soft palate and sealing off the nasal cavity completely. The exhaled breath carries medication from the device into one side of the nose through a specially shaped sealing nosepiece, balancing the pressure on the soft palate. Narrow nasal passages are gently expanded and medication is transported well beyond the nasal valve to targeted sites. After delivering medication to the targeted sites, air flows around to the opposite side of the nasal cavity and exits through the other side of the nose rather than into the throat or lungs.
OptiNose Media Contact
Sloane & Company